UPLYFT For Lymphoma Survivors

Last updated: March 25, 2025
Sponsor: Dana-Farber Cancer Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma

Treatment

Interview with Clinicians

Field Test of UPLYFT with Lymphoma Survivors

Pilot of UPLYFT with Lymphoma Survivors

Clinical Study ID

NCT05080166
21-409
  • Ages > 18
  • All Genders

Study Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Lymphoma Survivors Phase 1 and 2:

  • Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkinlymphoma, or classic Hodgkin lymphoma)

  • Age ≥ 18 years

  • Interval of 3 months to 24 months from completion of first-line treatment

  • In complete remission after first line of treatment

  • Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-SeveritySubscale [FCRI-SS).

  • Access to computer (for videoconferencing)

Lymphoma clinicians and mental health clinicians Phase 1:

  • Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental healthclinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completionof clinical training.

  • Longitudinal clinical care for patients with lymphoma by oncologists OR provision ofcare for patients with cancer by mental health clinicians

Exclusion

Exclusion Criteria:

Lymphoma Survivors Phase 1:

  • Age < 18 years

  • Concurrent other malignancy

  • Patients with uncontrolled/untreated psychotic disorders or untreated bipolar andborderline personality disorder (as ascertained from medical record screen).

Lymphoma Survivors Phase 2:

  • Age < 18 years

  • Concurrent other malignancy

  • Patients with uncontrolled/untreated psychotic disorders or untreated bipolar andborderline personality disorders (as ascertained from medical record screen).

  • Our study will exclude members of the following special populations:

  • Adults unable to consent

  • Individuals who are not yet adults (infants, children, teenagers)

  • Pregnant women

  • Prisoners

Study Design

Total Participants: 74
Treatment Group(s): 3
Primary Treatment: Interview with Clinicians
Phase:
Study Start date:
February 08, 2022
Estimated Completion Date:
March 31, 2026

Study Description

This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors.

Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program field test. Phase 2 is a randomized pilot study using the UPLFYT program finalized in Phase 1.

Research procedures include:

  • In depth interview (lymphoma and mental health clinicians)

  • Screening for eligibility

  • 6 weekly intervention sessions (lymphoma survivors)

  • Baseline Assessments and Questionnaires (lymphoma survivors)

    74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase 2.

The American Society of Hematology is providing funding for the trial.

Connect with a study center

  • Dana-Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.